Cipla’s arm receives two inspectional observations from USFDA

11 Feb 2026 Evaluate

Cipla’s wholly owned subsidiary -- InvaGen Pharmaceuticals, Inc. (InvaGen) has received two inspectional observations in Form 483 from United States Food and Drug Administration (USFDA) for its manufacturing facility located in Long Island, New York, USA. 

The USFDA had conducted a Pre-Approval Inspection (PAI) at the said manufacturing facility from February 2, 2026 to February 9, 2026.

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).

Cipla Share Price

1260.65 22.00 (1.78%)
20-Mar-2026 15:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.20
Dr. Reddys Lab 1295.00
Cipla 1260.65
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×